Here are three updates from gastroenterology companies from the past week:
Fujifilm is building a $36 million "smart" manufacturing facility in Tochigi, Japan, to double its endoscope production capability.
EndoGastric Solutions closed a $45 million series I round to fuel commercialization efforts around its TIF 2.0 procedure.
A phase 1 clinical trial found that Landos Biopharma's Crohn's disease and ulcerative colitis treatment, BT-11, was well-tolerated with no dose-limiting toxicities or detectable systemic immunosuppression.
More articles on gastroenterology:
Now-defunct Laser Spine Institute under fire over insurance handling — 5 key details
Washington passes surprise-billing law
3 ways ASCs can improve cash flow